SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 15, 2020
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
| Nevada | 001-38543 | 26-1265381 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| 400 Water Street, Suite 200, Rochester, MI | 48307 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: 248.651.6568
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol | Name of each exchange on which registered | ||
| Common Stock | OPRX | Nasdaq Capital Market |
SECTION 8 – Other Events
| Item 8.01 | Other Events |
On March 15, 2020, we issued a press release concerning the launch of a free interactive text message alert program available to the general public that delivers coronavirus (COVID-19) information issued by the Centers for Disease Control and Prevention (CDC) directly to any SMS-enabled mobile device. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
SECTION 9 – Financial Statements and Exhibits
| Item 9.01 | Financial Statements and Exhibits |
| 99.1 | Press release, dated March 15, 2020 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| OptimizeRx Corporation | |
| /s/ Douglas Baker | |
| Douglas Baker | |
| Chief Financial Officer | |
| Date March 16, 2020 |
2
Exhibit 99.1
OptimizeRx Launches Coronavirus Text Message Alerts
|
ROCHESTER, Mich. – March 15, 2020 – OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, has launched a free interactive text message alert program available to the general public that delivers coronavirus (COVID-19) information issued by the Centers for Disease Control and Prevention (CDC) directly to any SMS-enabled mobile device.
The COVID-19 Public Alert System was developed by the OptimizeRx patient engagement team to help the American public stay up-to date with authoritative, timely information about the spread of the virus and provide guidance for what to do if affected. |
 |
Text VIRUS to 55150 to subscribe to the service.
At no additional cost if you have an unlimited texting plan. Otherwise msg and data rates may apply. Msg frequency varies. Text HELP to 55150 for help. Text STOP to 55150 to cancel. Click here for terms of use.
Following your signup confirmation, you will begin to receive CDC-based COVID-19 information:
| ● | Health information and tips, including how to avoid contracting the virus and symptom warning signs. |
| ● | Information on testing and steps you can take to help contain the spread of COVID-19. |
| ● | Regular updates about COVID-19 based on CDC-issued information. |
| ● | Opt-in to alerts and additional opt-ins to continue receiving alerts and information. |
“In order to create the safest health environment possible for our local communities, it is critical that the public follows the recommendations of the CDC and other public health agencies,” said OptimizeRx CEO, William Febbo. “We are providing these CDC alerts using our digital health network as a public health service for both consumers and healthcare professionals. With this new COVID-19 Public Alert System, we are hoping to further the knowledge about this deadly virus for those potentially affected by it, in addition to the work we’re doing to keep those on the front lines treating patients informed.”
This new consumer message alert service complements the recently launched OptimizeRx CDC alert system for healthcare providers. The company is leveraging its expansive digital network, technology platform, and partnerships to provide CDC alerts as a public health service for both consumers and healthcare professionals.
“Easy mobile access to reliable and timely health information can make a big difference in staying safe and helping to contain the outbreak,” noted Serge Loncar, head of patient engagement at OptimizeRx. “We have harnessed the powerful capabilities of our mobile platform to broadly disseminate critical health information and updates about the coronavirus so that everyone can better care for themselves and their loved ones.”
About OptimizeRx
OptimizeRx® (NASDAQ: OPRX), a digital health company, connects pharmaceutical companies to patients and providers, offering greater affordability, adherence and brand awareness at the point-of-care. As the nation’s largest digital platform connecting life sciences to the point-of-care, OptimizeRx provides a direct channel for pharma companies, payers, medtech, and medical associations to communicate with healthcare providers right within their workflow and also directly to patients.
The cloud-based solution supports patient adherence to medications and better healthcare outcomes with real-time access to financial assistance, prior authorization, education and critical clinical information. OptimizeRx provides more than half of the ambulatory patient market with access to these benefits through leading EHR platforms like Allscripts, Amazing Charts and Quest, and directly via its mobile communications platform and digital therapeutics SaaS platform.
For more information, follow the company on Twitter, LinkedIn or visit www.OptimizeRx.com.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.
OptimizeRx Contact
Doug Baker, CFO
Tel (248) 651-6568 x807
dbaker@optimizerx.com
Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245 7070
malejandra@optimizerx.com
Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557
oprx@cma.team
A photo accompanying this announcement is available here.